Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
Scientists at King’s College London have developed an innovative IgE antibody therapy that activates the immune system to ...
Experts discuss the patient case of Janet, a 58-year-old with her 2 positive metastatic breast cancer, and after 14 months on ...
Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from ...
Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...
Asianet Newsable on MSN2d
New antibody reduces tumor growth in tough-to-treat breast and ovarian cancers: StudyImmunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being ...
Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...
News-Medical.Net on MSN7h
Moffitt researchers discover new vaccine strategy for treating specific type of breast cancerMoffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
Data presented at European Molecular Imaging Meeting (EMIM 2025) for imaging with 68Ga-RAD202 confirms specific accumulation in the tumor, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback